| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1053470348 |
| P356 | DOI | 10.1038/NRC3770 |
| P698 | PubMed publication ID | 24990523 |
| P5875 | ResearchGate publication ID | 263745664 |
| P50 | author | John C Bell | Q88475862 |
| Brian Dennis Lichty | Q89782416 | ||
| David F Stojdl | Q115626236 | ||
| P2093 | author name string | Caroline J Breitbach | |
| P2860 | cites work | Activation of P2X(7) receptor by ATP plays an important role in regulating inflammatory responses during acute viral infection | Q21134608 |
| Hallmarks of Cancer: The Next Generation | Q22252312 | ||
| New viruses for cancer therapy: meeting clinical needs | Q24567699 | ||
| Recombinant Newcastle disease virus as a vaccine vector for cancer therapy | Q24602728 | ||
| Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy | Q24605512 | ||
| Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers | Q24611483 | ||
| Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients | Q24617027 | ||
| Enhancing Efficacy of Recombinant Anticancer Vaccines With Prime/Boost Regimens That Use Two Different Vectors | Q73856260 | ||
| Cytokine-secreting herpes viral mutants effectively treat tumor in a murine metastatic colorectal liver model by oncolytic and T-cell-dependent mechanisms | Q80151821 | ||
| Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial | Q83427167 | ||
| Autophagy Mediates the Metabolic Benefits of Endurance Training | Q84121586 | ||
| Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma | Q84834335 | ||
| Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma | Q84906858 | ||
| Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors | Q42051381 | ||
| Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial | Q42687156 | ||
| Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus | Q43599369 | ||
| Monoclonal antibodies to phosphotyrosine | Q43671222 | ||
| Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. | Q44666172 | ||
| Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial | Q44883112 | ||
| Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells | Q45139053 | ||
| Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma | Q45358671 | ||
| China approves world's first oncolytic virus therapy for cancer treatment | Q45419325 | ||
| Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy | Q45420583 | ||
| Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system | Q45422016 | ||
| Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. | Q45423758 | ||
| Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand | Q45618074 | ||
| Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (alvac) cytokine gene delivery induces destruction of established prostate tumors | Q45734454 | ||
| A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes | Q45735745 | ||
| Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects. | Q45737842 | ||
| In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity. | Q45738606 | ||
| Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. | Q45856627 | ||
| The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma | Q46364445 | ||
| Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer | Q46448111 | ||
| Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model | Q48404550 | ||
| A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers | Q51800255 | ||
| Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy. | Q53675456 | ||
| Regulation of IL-15 secretion via the leader peptide of two IL-15 isoforms | Q71929898 | ||
| Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity. | Q39430229 | ||
| Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1. | Q39663316 | ||
| Tumor suppression by apoptotic and anti-angiogenic effects of mortalin-targeting adeno-oncolytic virus | Q39684064 | ||
| Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma | Q39796367 | ||
| Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. | Q39852211 | ||
| OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma | Q39866378 | ||
| Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses. | Q39887869 | ||
| Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy | Q39974313 | ||
| Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells | Q39991750 | ||
| A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes | Q40031348 | ||
| Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow | Q40117676 | ||
| Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor. | Q40130388 | ||
| Treatment of implanted mammary tumors with recombinant vesicular stomatitis virus targeted to Her2/neu. | Q40160049 | ||
| Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma | Q40186370 | ||
| Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus | Q40190051 | ||
| Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent mice | Q40312249 | ||
| Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models | Q40327891 | ||
| Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity | Q40601029 | ||
| Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression | Q40626041 | ||
| Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses | Q40736533 | ||
| Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule | Q40840410 | ||
| Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses | Q41117736 | ||
| Targeting the tumor mutanome for personalized vaccination therapy | Q41882039 | ||
| Potentiating cancer immunotherapy using an oncolytic virus | Q24628810 | ||
| Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4 | Q24634871 | ||
| Sipuleucel-T immunotherapy for castration-resistant prostate cancer | Q27860648 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Oncolytic effects of a novel influenza A virus expressing interleukin-15 from the NS reading frame | Q28483092 | ||
| Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus | Q28755816 | ||
| Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors | Q29615665 | ||
| Immunologic correlates of the abscopal effect in a patient with melanoma | Q29620334 | ||
| Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma | Q29622835 | ||
| Targeting tumor vasculature with an oncolytic virus | Q30500348 | ||
| Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial | Q33379689 | ||
| A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients | Q33382497 | ||
| A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers | Q33554262 | ||
| Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model | Q33710420 | ||
| Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL. | Q33730717 | ||
| Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus. | Q33832148 | ||
| Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma | Q33875659 | ||
| Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy | Q33933665 | ||
| Necroptosis: the release of damage-associated molecular patterns and its physiological relevance | Q34035754 | ||
| Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity | Q34096503 | ||
| Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients | Q34116267 | ||
| ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties | Q34178661 | ||
| Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans | Q34212910 | ||
| VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents | Q34273164 | ||
| Immunogenic cell death and DAMPs in cancer therapy | Q34311701 | ||
| Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer | Q34327051 | ||
| Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer | Q34543188 | ||
| Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. | Q34556808 | ||
| History of oncolytic viruses: genesis to genetic engineering | Q34575505 | ||
| A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. | Q34583808 | ||
| Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus | Q34680077 | ||
| Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. | Q34757261 | ||
| Sunitinib facilitates the activation and recruitment of therapeutic anti‐tumor immunity in concert with specific vaccination | Q35033957 | ||
| Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. | Q35039508 | ||
| Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1 | Q35060701 | ||
| Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy | Q35086690 | ||
| Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18Rα. | Q35204881 | ||
| Adoptive-cell-transfer therapy for the treatment of patients with cancer | Q35210008 | ||
| Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus | Q35238258 | ||
| A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma | Q35285695 | ||
| Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation | Q35531563 | ||
| The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers | Q35876204 | ||
| Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients | Q35889432 | ||
| The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic cell antigens to favor cross-priming of CTLs in virus-infected mice | Q35913706 | ||
| Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL | Q36209190 | ||
| Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4 | Q36488714 | ||
| Recombinant viral vectors: cancer vaccines | Q36618444 | ||
| Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress | Q36720873 | ||
| IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner | Q36855263 | ||
| Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. | Q36937117 | ||
| Trial watch: Oncolytic viruses for cancer therapy | Q37028023 | ||
| Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients | Q37068071 | ||
| Novel immunocompetent murine tumor model for evaluation of conditionally replication-competent (oncolytic) murine adenoviral vectors | Q37145300 | ||
| Suppression of Antiviral Innate Immunity by Sunitinib Enhances Oncolytic Virotherapy | Q37181377 | ||
| Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy | Q37194864 | ||
| Smac mimetics and innate immune stimuli synergize to promote tumor death | Q37270377 | ||
| Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus | Q37311960 | ||
| Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8. | Q37379408 | ||
| Maraba virus as a potent oncolytic vaccine vector | Q37562080 | ||
| Oncolytic virotherapy | Q38025263 | ||
| Gene-engineered T cells for cancer therapy | Q38123667 | ||
| Evolution of oncolytic viruses: novel strategies for cancer treatment | Q38159802 | ||
| Oncolytic and Immunotherapeutic Vaccinia Induces Antibody-Mediated Complement-Dependent Cancer Cell Lysis in Humans | Q38450392 | ||
| Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. | Q38453432 | ||
| Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress | Q38569435 | ||
| T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy | Q38648630 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 559-567 | |
| P577 | publication date | 2014-07-03 | |
| P1433 | published in | Nature Reviews Cancer | Q641657 |
| P1476 | title | Going viral with cancer immunotherapy | |
| P478 | volume | 14 |
| Q54461045 | A Comparative Safety Profile Assessment of Oncolytic Virus Therapy Based on Clinical Trials. |
| Q58609439 | A New Role for Vitamin D: The Enhancement of Oncolytic Viral Therapy in Pancreatic Cancer |
| Q89985187 | A Triple-Regulated Oncolytic Adenovirus Carrying MicroRNA-143 Exhibits Potent Antitumor Efficacy in Colorectal Cancer |
| Q61443285 | A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE) |
| Q40080717 | A practical guide to the handling and administration of talimogene laherparepvec in Europe |
| Q57192791 | APOBEC3 Mediates Resistance to Oncolytic Viral Therapy |
| Q40192795 | Activation of Nrf2 Signaling Augments Vesicular Stomatitis Virus Oncolysis via Autophagy-Driven Suppression of Antiviral Immunity |
| Q36028552 | Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study |
| Q38808823 | Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer |
| Q38924566 | Advances in the design and development of oncolytic measles viruses |
| Q52655195 | Advances in the mechanisms of action of cancer-targeting oncolytic viruses |
| Q38563884 | All that glitters is not gold: the need to consider desirable and undesirable immune aspects of oncolytic virus therapy |
| Q101226667 | Antitumor effects of IL-12 and GM-CSF co-expressed in an engineered oncolytic HSV-1 |
| Q38714964 | Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors |
| Q38470166 | Arming oncolytic viruses to leverage antitumor immunity |
| Q92058791 | Artificially cloaked viral nanovaccine for cancer immunotherapy |
| Q36664268 | Assessment of current virotherapeutic application schemes: "hit hard and early" versus "killing softly"? |
| Q91650568 | Biological treatment of pediatric sarcomas by combined virotherapy and NK cell therapy |
| Q36684345 | Biomaterials and emerging anticancer therapeutics: engineering the microenvironment. |
| Q47559036 | Brief Communication; A Heterologous Oncolytic Bacteria-Virus Prime-Boost Approach for Anticancer Vaccination in Mice. |
| Q92245332 | CAR T cells for brain tumors: Lessons learned and road ahead |
| Q36753953 | CD8(+) T-cell Immune Evasion Enables Oncolytic Virus Immunotherapy |
| Q36821243 | CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy |
| Q92345877 | Calcium Influx Caused by ER Stress Inducers Enhances Oncolytic Adenovirus Enadenotucirev Replication and Killing through PKCα Activation |
| Q38717141 | Cancer immunology and canine malignant melanoma: A comparative review |
| Q26752277 | Cancer immunotherapy: the beginning of the end of cancer? |
| Q50865520 | Capitalizing on Cancer Specific Replication: Oncolytic Viruses as a Versatile Platform for the Enhancement of Cancer Immunotherapy Strategies |
| Q35641491 | Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer |
| Q50619471 | Chemotherapeutic tumor microparticles combining low-dose irradiation reprogram tumor-promoting macrophages through a tumor-repopulating cell-curtailing pathway |
| Q36582785 | Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus |
| Q35149637 | Classification of current anticancer immunotherapies |
| Q26743393 | Clinical development of gene therapy: results and lessons from recent successes |
| Q38630561 | Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy. |
| Q58563112 | Clinical-Grade Oncolytic Adenovirus Purification Using Polysorbate 20 as an Alternative for Cell Lysis |
| Q57016734 | Combination of IAP Antagonists and TNF-α-Armed Oncolytic Viruses Induce Tumor Vascular Shutdown and Tumor Regression |
| Q35789319 | Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling |
| Q38924569 | Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy |
| Q38784057 | Computational modeling approaches to the dynamics of oncolytic viruses |
| Q38776765 | Constrained evolvability of interferon suppression in an RNA virus |
| Q57345004 | Controlling supramolecular polymerization through multicomponent self-assembly |
| Q41689720 | Cowpox Virus: A New and Armed Oncolytic Poxvirus |
| Q39387174 | Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy |
| Q55457323 | Current state of immunotherapy for glioblastoma. |
| Q36544290 | Cytokine-induced killer cells efficiently kill stem-like cancer cells of nasopharyngeal carcinoma via the NKG2D-ligands recognition |
| Q64245649 | Defining a murine ovarian cancer model for the evaluation of conditionally-replicative adenovirus (CRAd) virotherapy agents |
| Q37346447 | Design of virus-based nanomaterials for medicine, biotechnology, and energy |
| Q36142487 | Designing Herpes Viruses as Oncolytics |
| Q47547386 | Designing and building oncolytic viruses |
| Q45716103 | Development of a Curative Therapeutic Vaccine (TheraVac) for the Treatment of Large Established Tumors. |
| Q47549076 | Development of a Safe and Effective Vaccinia Virus Oncolytic Vector WR-Δ4 with a Set of Gene Deletions on Several Viral Pathways |
| Q36380295 | Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes. |
| Q38791776 | Development of an oncolytic HSV vector fully retargeted specifically to cellular EpCAM for virus entry and cell-to-cell spread. |
| Q50885033 | Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations |
| Q90096935 | Dilemma and Challenge of Immunotherapy for Pancreatic Cancer |
| Q92356810 | Directed evolution as a tool for the selection of oncolytic RNA viruses with desired phenotypes |
| Q47562626 | Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells |
| Q64272058 | Emerging Nano-/Microapproaches for Cancer Immunotherapy |
| Q38660577 | Engineered Materials for Cancer Immunotherapy. |
| Q26776373 | Engineering opportunities in cancer immunotherapy |
| Q55516215 | Enhanced Control of Oncolytic Measles Virus Using MicroRNA Target Sites. |
| Q55309857 | Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference. |
| Q38811582 | Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model. |
| Q36665114 | Enhancing the Tumor Selectivity of a Picornavirus Virotherapy Promotes Tumor Regression and the Accumulation of Infiltrating CD8+ T Cells |
| Q55689740 | EphA2 chimeric antigen receptor-modified T cells for the immunotherapy of esophageal squamous cell carcinoma. |
| Q57462027 | Estimation of Oncolytic Virus Populations within Tumors |
| Q36664249 | Evidence for differential viral oncolytic efficacy in an in vitro model of epithelial ovarian cancer metastasis |
| Q58707721 | Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology |
| Q26771799 | Exploring Reovirus Plasticity for Improving Its Use as Oncolytic Virus |
| Q55395331 | Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirus in murine cancer cells. |
| Q38612646 | Fighting Cancer with Mathematics and Viruses |
| Q64113944 | Fludarabine as an Adjuvant Improves Newcastle Disease Virus-Mediated Antitumor Immunity in Hepatocellular Carcinoma |
| Q35541787 | Gene and cell therapy for pancreatic cancer |
| Q38703318 | Gene therapy approaches against cancer using in vivo and ex vivo gene transfer of interleukin-12. |
| Q38607706 | Gene therapy returns to centre stage |
| Q64110950 | Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma |
| Q95327672 | Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment |
| Q28086999 | Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors |
| Q39387367 | Herpesviral vectors and their application in oncolytic therapy, vaccination, and gene transfer |
| Q26823674 | High-throughput screening to enhance oncolytic virus immunotherapy |
| Q36310887 | How to develop viruses into anticancer weapons |
| Q40611325 | How to train your oncolytic virus: the immunological sequel |
| Q56890107 | Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options |
| Q38878906 | Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges |
| Q45880480 | Immune-checkpoint blockade: the springboard for immuno-combination therapy. |
| Q56889817 | Immuno-Oncology: Emerging Targets and Combination Therapies |
| Q47732542 | Immunoengineering with biomaterials for enhanced cancer immunotherapy |
| Q38790788 | Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes |
| Q98952103 | Immunological considerations for COVID-19 vaccine strategies |
| Q37730966 | Immunotherapy for Esophageal Squamous Cell Carcinoma |
| Q57610999 | Infection and Cancer: Multi-directorial Relationship |
| Q33555975 | Infections and cancer: the "fifty shades of immunity" hypothesis |
| Q33621028 | Insertion of a ligand to HER2 in gB retargets HSV tropism and obviates the need for activation of the other entry glycoproteins. |
| Q59361065 | Integrating oncolytic viruses in combination cancer immunotherapy |
| Q49787495 | Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients |
| Q39043844 | Intratumoral Delivery of Immunotherapy-Act Locally, Think Globally |
| Q40607907 | Intratumoral Infection with Murine Cytomegalovirus Synergizes with PD-L1 Blockade to Clear Melanoma Lesions and Induce Long-term Immunity. |
| Q40099497 | Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells |
| Q37651860 | Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity |
| Q40982444 | Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy. |
| Q64906210 | In Vivo Imaging of Oncolytic Measles Virus Propagation with Single-Cell Resolution. |
| Q54221621 | Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy |
| Q52353493 | Local Immunotherapy of Cancer: Innovative Approaches to Harnessing Tumor-Specific Immune Responses. |
| Q39932965 | M011L-deficient oncolytic myxoma virus induces apoptosis in brain tumor-initiating cells and enhances survival in a novel immunocompetent mouse model of glioblastoma |
| Q96304986 | MAP3K7 and CHD1 Are Novel Mediators of Resistance to Oncolytic Vesicular Stomatitis Virus in Prostate Cancer Cells |
| Q38336989 | Mechanisms of tumor-induced T cell immune suppression and therapeutics to counter those effects |
| Q50089395 | Mechanisms regulating T-cell infiltration and activity in solid tumors |
| Q47109590 | Mesenchymal stem cells as therapeutic agents and in gene delivery for the treatment of glioma*. |
| Q40097287 | MicroRNAs as Important Players in Host-Adenovirus Interactions. |
| Q90348469 | Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy |
| Q37225501 | Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer |
| Q58701885 | Modulation of the Tumor Microenvironment by CXCR4 Antagonist-Armed Viral Oncotherapy Enhances the Antitumor Efficacy of Dendritic Cell Vaccines against Neuroblastoma in Syngeneic Mice |
| Q26752807 | Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses |
| Q47365404 | Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds |
| Q36751597 | Murine Tumor Models for Oncolytic Rhabdo-Virotherapy |
| Q26801067 | Nanotechnology: Future of Oncotherapy |
| Q38673407 | Neutralization of matrix metalloproteinase-9 potentially enhances oncolytic efficacy of tanapox virus for melanoma therapy. |
| Q39010098 | New chemical treatment options in second-line hepatocellular carcinoma: what to do when sorafenib fails? |
| Q38924557 | Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy |
| Q91705503 | Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect |
| Q38752688 | Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination |
| Q26776553 | Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications |
| Q41926865 | Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial. |
| Q38848223 | Oncolytic Immunotherapy for Treatment of Cancer |
| Q33679505 | Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives |
| Q91965047 | Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer |
| Q26825239 | Oncolytic Sendai virus-based virotherapy for cancer: recent advances |
| Q37129177 | Oncolytic Virus-Mediated Targeting of PGE2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to Immunotherapy |
| Q59349507 | Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines |
| Q39456860 | Oncolytic Viruses: Exploiting Cancer's Deal with the Devil |
| Q26741020 | Oncolytic Viruses: Therapeutics With an Identity Crisis |
| Q28083515 | Oncolytic adenovirus research evolution: from cell-cycle checkpoints to immune checkpoints |
| Q40200208 | Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation |
| Q33899522 | Oncolytic measles virus enhances antitumour responses of adoptive CD8+NKG2D+ cells in hepatocellular carcinoma treatment |
| Q40336053 | Oncolytic measles virus induces tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by human myeloid and plasmacytoid dendritic cells |
| Q39961118 | Oncolytic vesicular stomatitis virus expressing interferon-γ has enhanced therapeutic activity |
| Q59793501 | Oncolytic virotherapy – in vivo veritas |
| Q59793949 | Oncolytic virus immunotherapy: future prospects for oncology |
| Q59335236 | Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials |
| Q52309503 | Oncolytic viruses as engineering platforms for combination immunotherapy. |
| Q50423294 | Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells. |
| Q38919107 | Oncolytic viruses-immunotherapeutics on the rise |
| Q26772039 | Oncolytic viruses: finally delivering |
| Q43631043 | Oncolytic viruses: focusing on the tumor microenvironment |
| Q92099101 | Oncolytic viruses: overcoming translational challenges |
| Q26769977 | Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade |
| Q52674215 | PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. |
| Q26747524 | Pancreatic cancer from bench to bedside: molecular pathways and treatment options |
| Q54965295 | Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. |
| Q26821929 | Patient-derived mesenchymal stem cells as delivery vehicles for oncolytic virotherapy: novel state-of-the-art technology |
| Q37256174 | Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers |
| Q41706961 | Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection. |
| Q33648649 | Plasmodium parasite as an effective hepatocellular carcinoma antigen glypican-3 delivery vector |
| Q38764947 | Potential and clinical translation of oncolytic measles viruses |
| Q50055098 | Potentiating prostate cancer immunotherapy with oncolytic viruses |
| Q61796743 | Pre-surgical neoadjuvant oncolytic virotherapy confers protection against rechallenge in a murine model of breast cancer |
| Q38795324 | Preclinical Mouse Models for Analysis of the Therapeutic Potential of Engineered Oncolytic Herpes Viruses |
| Q47242457 | Preclinical Testing of an Oncolytic Parvovirus: Standard Protoparvovirus H-1PV Efficiently Induces Osteosarcoma Cell Lysis In Vitro. |
| Q54255264 | Preclinical development of peptide vaccination combined with oncolytic MG1-E6E7 for HPV-associated cancer |
| Q39868041 | Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy |
| Q36781992 | Progress in Adaptive Immunotherapy for Cancer in Companion Animals: Success on the Path to a Cure |
| Q39194052 | Progress in nonviral gene therapy for breast cancer and what comes next? |
| Q36308045 | Proinflammatory response induced by Newcastle disease virus in tumor and normal cells. |
| Q40465319 | Prospect and progress of oncolytic viruses for treating peripheral nerve sheath tumors. |
| Q57039785 | Protein-based nanoparticles in Cancer vaccine development |
| Q47549912 | Proteomic Analysis of Secretomes of Oncolytic Herpes Simplex Virus-Infected Squamous Cell Carcinoma Cells |
| Q37736296 | Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy |
| Q38886593 | Recent advances in oncolytic adenovirus therapies for cancer |
| Q30300159 | Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. |
| Q40084604 | Recombinant LCMV Vectors Induce Protective Immunity following Homologous and Heterologous Vaccinations. |
| Q27023902 | Regulation of human adenovirus alternative RNA splicing by the adenoviral L4-33K and L4-22K proteins |
| Q40064004 | Reovirus FAST Protein Enhances Vesicular Stomatitis Virus Oncolytic Virotherapy in Primary and Metastatic Tumor Models |
| Q33613549 | Replication and Oncolytic Activity of an Avian Orthoreovirus in Human Hepatocellular Carcinoma Cells |
| Q37502464 | Reprogramming antitumor immunity against chemoresistant ovarian cancer by a CXCR4 antagonist-armed viral oncotherapy |
| Q38734741 | Robust Oncolytic Virotherapy Induces Tumor Lysis Syndrome and Associated Toxicities in the MPC-11 Plasmacytoma Model |
| Q92049715 | SIRT1 Modulates the Sensitivity of Prostate Cancer Cells to Vesicular Stomatitis Virus Oncolysis |
| Q39389951 | STING-mediated DNA sensing in cancer immunotherapy |
| Q38879452 | Safety and antitumor effect of oncolytic and helper-dependent adenoviruses expressing interleukin-12 variants in a hamster pancreatic cancer model. |
| Q35670660 | Science to Practice: Monitoring Oncolytic Virus Therapy with Chemical Exchange Saturation Transfer MR Imaging--Wishful Thinking? |
| Q90346056 | Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses |
| Q40544557 | Single-particle characterization of oncolytic vaccinia virus by flow virometry. |
| Q37681801 | Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression |
| Q91714317 | Starvation-Induced Differential Virotherapy Using an Oncolytic Measles Vaccine Virus |
| Q38737706 | State of play and clinical prospects of antibody gene transfer |
| Q38364522 | Stem cell state and the epithelial-to-mesenchymal transition: Implications for cancer therapy |
| Q60956502 | Structured illumination microscopy combined with machine learning enables the high throughput analysis and classification of virus structure |
| Q56967396 | Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade |
| Q89736887 | Systemic oncolytic adenovirus delivered in mesenchymal carrier cells modulate tumor infiltrating immune cells and tumor microenvironment in mice with neuroblastoma |
| Q55085319 | Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies. |
| Q40336558 | Tanapoxvirus lacking the 15L gene inhibits melanoma cell growth in vitro by inducing interferon-λ1 release |
| Q100427929 | Targeted scavenging of extracellular ROS relieves suppressive immunogenic cell death |
| Q38676416 | Targeting Melanoma with Cancer-Killing Viruses |
| Q55051893 | Targeting Poxvirus Decapping Enzymes and mRNA Decay to Generate an Effective Oncolytic Virus. |
| Q35924903 | The Cytolytic Amphipathic β(2,2)-Amino Acid LTX-401 Induces DAMP Release in Melanoma Cells and Causes Complete Regression of B16 Melanoma |
| Q35638350 | The Engineering of a Novel Ligand in gH Confers to HSV an Expanded Tropism Independent of gD Activation by Its Receptors |
| Q88158673 | The Immune System in Oncolytic Immunovirotherapy: Gospel, Schism and Heresy |
| Q40182196 | The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers |
| Q100438293 | The Oncolytic Virus in Cancer Diagnosis and Treatment |
| Q89597106 | The Susceptibility of Human Melanoma Cells to Infection with the Leningrad-16 Vaccine Strain of Measles Virus |
| Q35417571 | The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy |
| Q27002660 | The ex vivo purge of cancer cells using oncolytic viruses: recent advances and clinical implications |
| Q52594999 | The importance of imaging strategies for pre-clinical and clinical in vivo distribution of oncolytic viruses |
| Q92003245 | The transporters SLC35A1 and SLC30A1 play opposite roles in cell survival upon VSV virus infection |
| Q41592594 | Therapeutic vaccine to cure large mouse hepatocellular carcinomas |
| Q27005830 | Towards an HIV cure based on targeted killing of infected cells: different approaches against acute versus chronic infection |
| Q59358819 | Transforming the prostatic tumor microenvironment with oncolytic virotherapy |
| Q28078725 | Trial Watch-Immunostimulation with cytokines in cancer therapy |
| Q28072347 | Trial Watch-Oncolytic viruses and cancer therapy |
| Q56892924 | Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy |
| Q90326778 | Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors |
| Q35522211 | Tumor Selectivity of Oncolytic Parvoviruses: From in vitro and Animal Models to Cancer Patients |
| Q89966648 | Tumor-targeting oncolytic virus elicits potent immunotherapeutic vaccine responses to tumor antigens |
| Q55509278 | Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses. |
| Q47709474 | Two is better than one: advances in pathogen-boosted immunotherapy and adoptive T-cell therapy |
| Q38747126 | Type I interferon responses are impaired in latently HIV infected cells. |
| Q35657822 | Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacy |
| Q40163884 | Use of adjuvants for immunotherapy. |
| Q26752522 | Vaccine adjuvants as potential cancer immunotherapeutics |
| Q38769021 | Vaccines for established cancer: overcoming the challenges posed by immune evasion |
| Q56889716 | Vaccinia Virus Shuffling: deVV5, a Novel Chimeric Poxvirus with Improved Oncolytic Potency |
| Q92628462 | Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE) |
| Q41706953 | Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC |
| Q36642808 | Viral-mimicking protein nanoparticle vaccine for eliciting anti-tumor responses. |
| Q26774641 | Viro-immune therapy: A new strategy for treatment of pancreatic cancer |
| Q55085114 | Viroimmunotherapy for Colorectal Cancer: Clinical Studies. |
| Q90414077 | Virus-Receptor Interactions and Virus Neutralization: Insights for Oncolytic Virus Development |
| Q45324998 | Virus-like nanoparticles: emerging tools for targeted cancer diagnostics and therapeutics. |
| Q56991805 | Visualizing Oncolytic Virus-Host Interactions in Live Mice Using Intravital Microscopy |
| Q28086839 | What next for newly diagnosed glioblastoma? |
| Q59358702 | [Immunotherapy - The New Era of Oncology] |
| Q89704640 | oHSV2 Can Target Murine Colon Carcinoma by Altering the Immune Status of the Tumor Microenvironment and Inducing Antitumor Immunity |
Search more.